Brief: Sino Biopharmaceutical Reports HY Profit Attributable RMB1.26 BLN
25/08/2023 09:42
Aug 25 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* SINO BIOPHARMACEUTICAL - HY PROFIT ATTRIBUTABLE RMB1.26
BILLION
VERSUS RMB1.92 BILLION
* SINO BIOPHARMACEUTICAL-HY REVENUE RMB15.28 BILLION VERSUS
RMB15.19 BILLION
* SINO BIOPHARMACEUTICAL-BOARD OF COMPANY HAS DECLARED
PAYMENT OF
AN INTERIM DIVIDEND OF HK2 CENTS PER SHARE FOR HY
* SINO BIOPHARMACEUTICAL-GROUP TARGETS TO MAKE ANNUAL
REVENUE OF
HK$100 BILLION BY 2030
Source text for Eikon: ID:nHKS1X0TwN
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up